PMC:7195088 / 49580-50363 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1480","span":{"begin":193,"end":201},"obj":"Species"},{"id":"1481","span":{"begin":156,"end":167},"obj":"Chemical"},{"id":"1482","span":{"begin":171,"end":189},"obj":"Chemical"},{"id":"1483","span":{"begin":594,"end":605},"obj":"Chemical"},{"id":"1484","span":{"begin":606,"end":624},"obj":"Chemical"},{"id":"1485","span":{"begin":207,"end":215},"obj":"Disease"}],"attributes":[{"id":"A1480","pred":"tao:has_database_id","subj":"1480","obj":"Tax:9606"},{"id":"A1481","pred":"tao:has_database_id","subj":"1481","obj":"MESH:D002738"},{"id":"A1482","pred":"tao:has_database_id","subj":"1482","obj":"MESH:D006886"},{"id":"A1483","pred":"tao:has_database_id","subj":"1483","obj":"MESH:D002738"},{"id":"A1484","pred":"tao:has_database_id","subj":"1484","obj":"MESH:D006886"},{"id":"A1485","pred":"tao:has_database_id","subj":"1485","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Recently, Cortegiani et al. [40] reviewed the available information on ongoing case series, comparative observational studies and RCT evaluating the use of chloroquine or hydroxychloroquine in patients with COVID-19 and registered in Chinese or US registries. They found 23 studies, all being conducted in China. However, in the few weeks after the paper was made available online (10 March 2020), the number of registered studies being conducted in countries other than China has multiplied (Table 2). In particular, results of registered RCT are necessary to guide (or discourage) the use of chloroquine/hydroxychloroquine in two different settings: prophylaxis of exposed individuals and treatment of proven cases, stratified for the severity of clinical presentation/progression."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T274","span":{"begin":207,"end":215},"obj":"Disease"}],"attributes":[{"id":"A274","pred":"mondo_id","subj":"T274","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Recently, Cortegiani et al. [40] reviewed the available information on ongoing case series, comparative observational studies and RCT evaluating the use of chloroquine or hydroxychloroquine in patients with COVID-19 and registered in Chinese or US registries. They found 23 studies, all being conducted in China. However, in the few weeks after the paper was made available online (10 March 2020), the number of registered studies being conducted in countries other than China has multiplied (Table 2). In particular, results of registered RCT are necessary to guide (or discourage) the use of chloroquine/hydroxychloroquine in two different settings: prophylaxis of exposed individuals and treatment of proven cases, stratified for the severity of clinical presentation/progression."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T289","span":{"begin":477,"end":480},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"Recently, Cortegiani et al. [40] reviewed the available information on ongoing case series, comparative observational studies and RCT evaluating the use of chloroquine or hydroxychloroquine in patients with COVID-19 and registered in Chinese or US registries. They found 23 studies, all being conducted in China. However, in the few weeks after the paper was made available online (10 March 2020), the number of registered studies being conducted in countries other than China has multiplied (Table 2). In particular, results of registered RCT are necessary to guide (or discourage) the use of chloroquine/hydroxychloroquine in two different settings: prophylaxis of exposed individuals and treatment of proven cases, stratified for the severity of clinical presentation/progression."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T99101","span":{"begin":156,"end":167},"obj":"Chemical"},{"id":"T35786","span":{"begin":171,"end":189},"obj":"Chemical"},{"id":"T33236","span":{"begin":594,"end":605},"obj":"Chemical"},{"id":"T38375","span":{"begin":606,"end":624},"obj":"Chemical"}],"attributes":[{"id":"A54959","pred":"chebi_id","subj":"T99101","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A69653","pred":"chebi_id","subj":"T35786","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A79527","pred":"chebi_id","subj":"T33236","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A9136","pred":"chebi_id","subj":"T38375","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"}],"text":"Recently, Cortegiani et al. [40] reviewed the available information on ongoing case series, comparative observational studies and RCT evaluating the use of chloroquine or hydroxychloroquine in patients with COVID-19 and registered in Chinese or US registries. They found 23 studies, all being conducted in China. However, in the few weeks after the paper was made available online (10 March 2020), the number of registered studies being conducted in countries other than China has multiplied (Table 2). In particular, results of registered RCT are necessary to guide (or discourage) the use of chloroquine/hydroxychloroquine in two different settings: prophylaxis of exposed individuals and treatment of proven cases, stratified for the severity of clinical presentation/progression."}

{"project":"LitCovid-sentences","denotations":[{"id":"T381","span":{"begin":0,"end":259},"obj":"Sentence"},{"id":"T382","span":{"begin":260,"end":312},"obj":"Sentence"},{"id":"T383","span":{"begin":313,"end":502},"obj":"Sentence"},{"id":"T384","span":{"begin":503,"end":783},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Recently, Cortegiani et al. [40] reviewed the available information on ongoing case series, comparative observational studies and RCT evaluating the use of chloroquine or hydroxychloroquine in patients with COVID-19 and registered in Chinese or US registries. They found 23 studies, all being conducted in China. However, in the few weeks after the paper was made available online (10 March 2020), the number of registered studies being conducted in countries other than China has multiplied (Table 2). In particular, results of registered RCT are necessary to guide (or discourage) the use of chloroquine/hydroxychloroquine in two different settings: prophylaxis of exposed individuals and treatment of proven cases, stratified for the severity of clinical presentation/progression."}